Search research articles
Contact Us
Filters
Showing results (31-40 of 66) with videos related to
Page
of 7
Sort By:
Trials
|
June 17, 2024
Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study
Parveen Fathima, Mark Jones, Reena D'Souza, et al.
Journal of Gastroenterology and Hepatology
|
December 17, 2024
Natural History and Predictors of Clinical Outcomes in Autoimmune Liver Diseases: A Multicenter Study
Dujinthan Jayabalan, Yi Huang, Luis Calzadilla-Bertot, et al.
Journal of Gastroenterology
|
January 19, 2018
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection
Stefan Zeuzem, Lawrence Serfaty, John Vierling, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)
|
April 24, 2014
Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives
David Victorson, Noelle E Carlozzi, Samuel Frank, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)
|
April 25, 2014
HD-PRO-TRIAD™ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease
Noelle E Carlozzi, David Victorson, Victor Sung, et al.
Antiviral Therapy
|
June 27, 2017
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir
David Wyles, Alessandra Mangia, Wendy Cheng, et al.
Antiviral Therapy
|
March 31, 2011
Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients
Cristina Baleriola, William D Rawlinson, Gregory J Dore, et al.
Journal of Hepatology
|
December 3, 2014
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
Kosh Agarwal, Scott K Fung, Tuan T Nguyen, et al.
Journal of Gastroenterology and Hepatology
|
November 14, 2013
Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies
Stuart K Roberts, Joanne Mitchell, Reynold Leung, et al.
World Journal of Hepatology
|
October 1, 2024
Predictors of survival in autoimmune liver disease overlap syndromes
Dujinthan Jayabalan, Yi Huang, Luis Calzadilla-Bertot, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 66) with videos related to
Sort By:
Page
of 7
Trials
|
June 17, 2024
Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study
Parveen Fathima, Mark Jones, Reena D'Souza, et al.
Journal of Gastroenterology and Hepatology
|
December 17, 2024
Natural History and Predictors of Clinical Outcomes in Autoimmune Liver Diseases: A Multicenter Study
Dujinthan Jayabalan, Yi Huang, Luis Calzadilla-Bertot, et al.
Journal of Gastroenterology
|
January 19, 2018
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection
Stefan Zeuzem, Lawrence Serfaty, John Vierling, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)
|
April 24, 2014
Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives
David Victorson, Noelle E Carlozzi, Samuel Frank, et al.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)
|
April 25, 2014
HD-PRO-TRIAD™ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease
Noelle E Carlozzi, David Victorson, Victor Sung, et al.
Antiviral Therapy
|
June 27, 2017
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir
David Wyles, Alessandra Mangia, Wendy Cheng, et al.
Antiviral Therapy
|
March 31, 2011
Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients
Cristina Baleriola, William D Rawlinson, Gregory J Dore, et al.
Journal of Hepatology
|
December 3, 2014
Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection
Kosh Agarwal, Scott K Fung, Tuan T Nguyen, et al.
Journal of Gastroenterology and Hepatology
|
November 14, 2013
Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies
Stuart K Roberts, Joanne Mitchell, Reynold Leung, et al.
World Journal of Hepatology
|
October 1, 2024
Predictors of survival in autoimmune liver disease overlap syndromes
Dujinthan Jayabalan, Yi Huang, Luis Calzadilla-Bertot, et al.
Page
of 7